Design of experiments

Tigermed Lauded by Frost & Sullivan for Its Rapid, Large-Scale Clinical Developmental Services

Tuesday, June 2, 2020 - 3:00pm

LONDON, June 2, 2020 /PRNewswire/ --Based on its recent analysis of the Chinese contract research organizations (CROs) market, Frost & Sullivan recognizes Tigermed with the 2020 Chinese Customer Value Leadership Awardfor its full clinical developmental services.

Key Points: 
  • LONDON, June 2, 2020 /PRNewswire/ --Based on its recent analysis of the Chinese contract research organizations (CROs) market, Frost & Sullivan recognizes Tigermed with the 2020 Chinese Customer Value Leadership Awardfor its full clinical developmental services.
  • Tigermed's clinical trial services include regulatory affairs, biometrics, clinical operations and data management, and post-marketing studies.
  • Additionally, its host of value-added clinical services cover areas such as imaging, pharmacovigilance, and central laboratory services..
  • "We are honored to be recognized by Frost & Sullivan," said Xiaochun Cao, Co-founder, Executive Director and General Manager of Tigermed.

Tigermed Lauded by Frost & Sullivan for Its Rapid, Large-Scale Clinical Developmental Services

Tuesday, June 2, 2020 - 3:00pm

LONDON, June 2, 2020 /PRNewswire/ --Based on its recent analysis of the Chinese contract research organizations (CROs) market, Frost & Sullivan recognizes Tigermed with the 2020 Chinese Customer Value Leadership Awardfor its full clinical developmental services.

Key Points: 
  • LONDON, June 2, 2020 /PRNewswire/ --Based on its recent analysis of the Chinese contract research organizations (CROs) market, Frost & Sullivan recognizes Tigermed with the 2020 Chinese Customer Value Leadership Awardfor its full clinical developmental services.
  • Tigermed's clinical trial services include regulatory affairs, biometrics, clinical operations and data management, and post-marketing studies.
  • Additionally, its host of value-added clinical services cover areas such as imaging, pharmacovigilance, and central laboratory services..
  • "We are honored to be recognized by Frost & Sullivan," said Xiaochun Cao, Co-founder, Executive Director and General Manager of Tigermed.

NW Bio Provides Update On Projected Timing For Data Lock For Phase 3 Trial of DCVax®-L for Glioblastoma Brain Cancer

Tuesday, June 2, 2020 - 2:35pm

The completion process includes final data collection, identification and resolution of queries, data checking and confirmation, and site sign-offs.

Key Points: 
  • The completion process includes final data collection, identification and resolution of queries, data checking and confirmation, and site sign-offs.
  • The service firms have completed the final monitoring visits to the trial sites (including a number of them virtually).
  • It is too early to determine what effect this update of the anticipated timing of data lock may have on the anticipated timing of the public announcement of data.
  • There may be a similar update to the timing of the announcement of the data as to the timing of the data lock.

Citius Receives Positive FDA Feedback on Its Submitted Plan to Study Catheter Compatibility for Mino-Lok® Therapy

Tuesday, June 2, 2020 - 2:30pm

The catheter compatibility studies will be conducted in parallel with the completion of the ongoing Phase 3 clinical study.

Key Points: 
  • The catheter compatibility studies will be conducted in parallel with the completion of the ongoing Phase 3 clinical study.
  • The Company announced in early February 2020 that this pivotal trial had reached the halfway point for enrollment.
  • "We believe we continue to check all the boxes required for an NDA submission," commented Myron Holubiak, Chief Executive Officer of Citius.
  • This would be between 10 to 14 hours of aggregate, but intermittent, exposure time of the catheter to Mino-Lok.

Global Prostate Cancer Clinical Trial Pipeline Highlights 2020, Segmented by Clinical Trial Stage, Drug Mechanism Class and Company - ResearchAndMarkets.com

Tuesday, June 2, 2020 - 4:30pm

The "Global Prostate Cancer Clinical Trial Pipeline Highlights - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Prostate Cancer Clinical Trial Pipeline Highlights - 2020" report has been added to ResearchAndMarkets.com's offering.
  • This report provides the most up-to-date information on key pipeline products in the global Prostate Cancer market.
  • It covers emerging therapies for Prostate Cancer in active clinical development stages including early and late-stage clinical trials.
  • The report provides Prostate Cancer pipeline products by clinical trial stages including both early and late-stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

YPrime Launches eCOA Solution to Enhance the Patient Experience in Clinical Trials

Tuesday, June 2, 2020 - 2:00pm

"The rapid adoption of eCOA is driving the future digital transformation of clinical research, said Michael Hughes, Senior Vice President, Product Development/Aubrey Llanes, eCOA Product Director.

Key Points: 
  • "The rapid adoption of eCOA is driving the future digital transformation of clinical research, said Michael Hughes, Senior Vice President, Product Development/Aubrey Llanes, eCOA Product Director.
  • "The key difference between today's clinical trial and the virtual model is the shift to the patients' domain as the center of activity.
  • All eCOA deployments are supported by experienced project managers and global helpdesk coverage to ensure fit-for-purpose solution design, risk management throughout a clinical study and quick resolution of technical issues.
  • eCOA and interactive response technology (IRT) platforms introduce greater speed, precision and data quality to clinical trials.

2020 Global Post-Operative Pain Clinical Trial Pipeline Highlights: Pipeline Products to be Launched Up to 2025 - ResearchAndMarkets.com

Tuesday, June 2, 2020 - 12:39pm

This report provides the most up-to-date information on key pipeline products in the global Post-Operative Pain market.

Key Points: 
  • This report provides the most up-to-date information on key pipeline products in the global Post-Operative Pain market.
  • It covers emerging therapies for Post-Operative Pain in active clinical development stages including early and late-stage clinical trials.
  • The report provides Post-Operative Pain pipeline products by clinical trial stages including both early and late-stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.
  • Find out which Post-Operative Pain pipeline products will be launched in the US and beyond to 2025.

2020 Global Colorectal Cancer Clinical Trial Pipeline Highlights - ResearchAndMarkets.com

Tuesday, June 2, 2020 - 12:01pm

The "Global Colorectal Cancer Clinical Trial Pipeline Highlights - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Colorectal Cancer Clinical Trial Pipeline Highlights - 2020" report has been added to ResearchAndMarkets.com's offering.
  • This report provides the most up-to-date information on key pipeline products in the global colorectal cancer market.
  • It covers emerging therapies for Colorectal Cancer in active clinical development stages including early and late-stage clinical trials.
  • The report provides Colorectal Cancer pipeline products by clinical trial stages including both early and late-stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Clinical Ink Implements COVID-19 Therapy Trial in Three Weeks

Tuesday, June 2, 2020 - 1:00pm

Clinical Ink , a global clinical trial technology company, has helped expedite the study of a treatment for cytokine storm, the immunological reaction associated with severe cases of COVID-19.

Key Points: 
  • Clinical Ink , a global clinical trial technology company, has helped expedite the study of a treatment for cytokine storm, the immunological reaction associated with severe cases of COVID-19.
  • When you want to receive and analyze data quickly, being able to condense build times to meet urgent deadlines makes all the difference, said Clinical Ink CEO Ed Seguine .
  • To learn more about Clinical Inks virtual trial offerings and capabilities, download their fact sheet .
  • Clinical Ink, a global clinical technology company, offers data certainty from source to submission.

QPS Awarded Two 2020 CRO Leadership Awards

Tuesday, June 2, 2020 - 11:55am

An award-winning leader focused on bioanalytics and clinical trials, QPS, has been awarded two 2020 CRO Leadership Awards by Life Science Leader magazine.

Key Points: 
  • An award-winning leader focused on bioanalytics and clinical trials, QPS, has been awarded two 2020 CRO Leadership Awards by Life Science Leader magazine.
  • In 2019, QPS also received two CRO Leadership Awards, which recognized QPS for excellence in Reliability (Big Pharma) and Quality (Big Pharma).
  • The CRO Leadership Awards were developed in 2012 to facilitate the vetting process for selecting outsourcing partners.
  • That is whywe are once again proud to partner with Industry Standard Research to produce ourannual CRO Leadership Awards.